In 2002 Davies et al identified BRAF somatic missense mutations in 66% of malignant melanomas; in 80% of cases it was a single substitution (V599E) within the kinase domain, which resulted in a constitutively active protein (3). This evidence concerns the gene BRAF and melanoma.